Li C, Ou R, Wei Q, Shang H
Novo Nordisk followed in 2025 with NovoCare Pharmacy, focused on stabilizing access to its high-demand GLP-1 therapies Wegovy and Ozempic, providing transparent cash-pay rails by publishing flat prices for GLP-1 therapies
Dr Reddy's is planning a rollout of semaglutide across 87 countries next year, with day 1 launches in India and Brazil as patents expire
Send a quick message through our contact form
Country of Manufacture: Facilities in countries with strict GMP (Good Manufacturing Practice) standards (e.g., USA, EU) tend to follow higher quality controls
Over the eight hybrids selected, five had improved stability in mouse plasma with the insertion of the triad at various positions on the peptide